Annual Accounts Payable
$6.50 M
+$585.00 K+9.88%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual accounts payable is currently $6.50 million, with the most recent change of +$585.00 thousand (+9.88%) on 31 December 2023. During the last 3 years, it has risen by +$1.69 million (+35.19%). EYPT annual accounts payable is now -13.69% below its all-time high of $7.54 million, reached on 30 June 2007.EYPT Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$7.34 M
-$6.95 M-48.64%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly accounts payable is currently $7.34 million, with the most recent change of -$6.95 million (-48.64%) on 30 September 2024. Over the past year, it has dropped by -$2.24 million (-23.35%). EYPT quarterly accounts payable is now -48.64% below its all-time high of $14.30 million, reached on 30 June 2024.EYPT Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +9.9% | -23.4% |
| 3 y3 years | +35.2% | +10.6% |
| 5 y5 years | +146.4% | +34.5% |
EYPT Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -11.9% | +35.2% | -48.6% | +24.1% |
| 5 y | 5 years | -11.9% | +146.4% | -48.6% | +89.2% |
| alltime | all time | -13.7% | +2190.1% | -48.6% | +4072.2% |
EyePoint Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $7.34 M(-48.6%) |
| June 2024 | - | $14.30 M(+101.9%) |
| Mar 2024 | - | $7.08 M(+8.9%) |
| Dec 2023 | $6.50 M(+9.9%) | $6.50 M(-32.1%) |
| Sept 2023 | - | $9.58 M(-10.6%) |
| June 2023 | - | $10.72 M(+13.4%) |
| Mar 2023 | - | $9.45 M(+59.7%) |
| Dec 2022 | $5.92 M(-19.9%) | $5.92 M(-3.2%) |
| Sept 2022 | - | $6.11 M(-13.4%) |
| June 2022 | - | $7.06 M(-3.3%) |
| Mar 2022 | - | $7.30 M(-1.1%) |
| Dec 2021 | $7.38 M(+53.5%) | $7.38 M(+11.2%) |
| Sept 2021 | - | $6.64 M(+22.5%) |
| June 2021 | - | $5.42 M(-7.4%) |
| Mar 2021 | - | $5.86 M(+21.7%) |
| Dec 2020 | $4.81 M(+14.8%) | $4.81 M(-7.2%) |
| Sept 2020 | - | $5.18 M(+33.6%) |
| June 2020 | - | $3.88 M(-24.7%) |
| Mar 2020 | - | $5.16 M(+23.0%) |
| Dec 2019 | $4.19 M(+58.8%) | $4.19 M(-23.2%) |
| Sept 2019 | - | $5.46 M(-10.0%) |
| June 2019 | - | $6.07 M(-4.0%) |
| Mar 2019 | - | $6.32 M(+55.0%) |
| Dec 2018 | $2.64 M(-10.2%) | - |
| Sept 2018 | - | $4.08 M(+38.6%) |
| June 2018 | $2.94 M(+189.4%) | $2.94 M(+6.5%) |
| Mar 2018 | - | $2.76 M(+86.1%) |
| Dec 2017 | - | $1.48 M(-15.5%) |
| Sept 2017 | - | $1.76 M(+72.8%) |
| June 2017 | $1.02 M(-25.5%) | $1.02 M(+37.1%) |
| Mar 2017 | - | $741.00 K(-33.2%) |
| Dec 2016 | - | $1.11 M(+9.4%) |
| Sept 2016 | - | $1.01 M(-25.5%) |
| June 2016 | $1.36 M(+83.2%) | $1.36 M(+138.7%) |
| Mar 2016 | - | $571.00 K(+88.4%) |
| Dec 2015 | - | $303.00 K(-66.1%) |
| Sept 2015 | - | $893.00 K(+20.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2015 | $744.00 K(+60.3%) | $744.00 K(-8.4%) |
| Mar 2015 | - | $812.00 K(+111.5%) |
| Dec 2014 | - | $384.00 K(-65.2%) |
| Sept 2014 | - | $1.10 M(+138.1%) |
| June 2014 | $464.00 K(-30.8%) | $464.00 K(-39.0%) |
| Mar 2014 | - | $761.00 K(+332.4%) |
| Dec 2013 | - | $176.00 K(-83.7%) |
| Sept 2013 | - | $1.08 M(+61.3%) |
| June 2013 | $671.00 K(+70.3%) | $671.00 K(+89.0%) |
| Mar 2013 | - | $355.00 K(+65.1%) |
| Dec 2012 | - | $215.00 K(-19.2%) |
| Sept 2012 | - | $266.00 K(-32.5%) |
| June 2012 | $394.00 K(+20.1%) | $394.00 K(+13.9%) |
| Mar 2012 | - | $346.00 K(+32.1%) |
| Dec 2011 | - | $262.00 K(-48.7%) |
| Sept 2011 | - | $511.00 K(+55.8%) |
| June 2011 | $328.00 K(-15.2%) | $328.00 K(+2.5%) |
| Mar 2011 | - | $320.00 K(-10.1%) |
| Sept 2010 | - | $356.00 K(-8.0%) |
| June 2010 | $387.00 K(+36.3%) | $387.00 K(-18.0%) |
| Mar 2010 | - | $472.00 K(+52.8%) |
| Dec 2009 | - | $309.00 K(-24.1%) |
| Sept 2009 | - | $407.00 K(+43.3%) |
| June 2009 | $284.00 K(-89.2%) | $284.00 K(-32.2%) |
| Mar 2009 | - | $419.00 K(+12.0%) |
| Dec 2008 | - | $374.00 K(-49.3%) |
| Sept 2008 | - | $737.00 K(-72.0%) |
| June 2008 | $2.63 M(-65.0%) | $2.63 M(-22.2%) |
| Mar 2008 | - | $3.38 M(-54.3%) |
| Dec 2007 | - | $7.41 M(+1.4%) |
| Sept 2007 | - | $7.30 M(-3.1%) |
| June 2007 | $7.54 M(+36.9%) | $7.54 M(-12.6%) |
| Dec 2006 | - | $8.62 M(+56.6%) |
| June 2006 | $5.51 M(+259.3%) | $5.51 M(+259.3%) |
| June 2005 | $1.53 M(+89.7%) | $1.53 M(+89.7%) |
| June 2004 | $807.70 K(+122.5%) | $807.70 K(+122.5%) |
| June 2003 | $363.00 K | $363.00 K |
FAQ
- What is EyePoint Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual accounts payable year-on-year change?
- What is EyePoint Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly accounts payable year-on-year change?
What is EyePoint Pharmaceuticals annual accounts payable?
The current annual accounts payable of EYPT is $6.50 M
What is the all time high annual accounts payable for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual accounts payable is $7.54 M
What is EyePoint Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, EYPT annual accounts payable has changed by +$585.00 K (+9.88%)
What is EyePoint Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of EYPT is $7.34 M
What is the all time high quarterly accounts payable for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly accounts payable is $14.30 M
What is EyePoint Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, EYPT quarterly accounts payable has changed by -$2.24 M (-23.35%)